DBV Technologies Breaks Key Support Ahead of Its General Meeting
The French biotech company falls midday, bucking the trend of a well-oriented SBF 120. The stock breaks a closely watched technical threshold downwards on the eve of its mixed general assembly.
MM20 and MM50 Under Pressure, While RSI Remains Neutral
DBV Technologies stock drops 1.79% to €3.18, against a 0.57% rise in the SBF 120. During the session, the stock broke through its support level at €3.19, a level that had been tested frequently in recent weeks, and is now trading just below it. The French biotech remains below its MM20 at €3.33 (a gap of -4.5%) and its MM50 at €3.45 (-7.8%), confirming a short-term negative dynamic. The RSI at 45 remains neutral and does not indicate seller exhaustion. The decline continues a difficult month, with a loss of 12.4% over thirty days and 11.4% over the quarter. However, the performance over the year remains largely positive, at over 112%, and the price is still above its MM200 at €2.95.
Rapid Increase in Short Positions and Mixed General Assembly on June 3
According to reviewed statements, two funds cumulatively hold 2.90% of the capital sold short, compared to 1.50% thirty days ago, marking a 1.4 point increase in a month. This rise reflects a more cautious institutional positioning around the stock, though it does not constitute a standalone signal: the portion of the float concerned remains limited, and multiple interpretations (exposure coverage, directional bet) can coexist. On the schedule, the mixed general assembly is set for tomorrow, Wednesday, June 3, 2026, at Châtillon (corporate headquarters). The stock is moving in a busy sectoral context for biotechs listed in Paris, with Abivax at the bottom of the SBF 120 (-31.22%) and Nanobiotix (-3.58%) among the notable declines of the day. The next technical reference point downwards, if the decline continues, would be at the MM200 at €2.95.
